Enoxaparin: In the prevention of venous thromboembolism in medical patients

American Journal of Cardiovascular Drugs

Volumn 1, Issue 6, 2001, Pages 477-481

  Warner, Gregory T ^a,b   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b Aids International Limited   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN;

CLINICAL TRIAL; HUMAN; REVIEW; THROMBOEMBOLISM;

ANTICOAGULANTS; CLINICAL TRIALS; ENOXAPARIN; HUMANS; THROMBOEMBOLISM;

EID: 1842564163     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/00129784-200101060-00010     Document Type: Article

References (14)

1. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999 Sep 9; 341: 793-800
2. Lechler E, Schramm W, Flosbach CW, et al. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). Haemostasis 1996 Mar; 26 Suppl. 2 (Suppl. 2): 49-56
3. Kleber FX, Flosbach CW, Koppenhagen K, et al. Comparison of the low molecular weight heparin enoxaparin with unfractionated heparin in the prevention of venous thromboembolic events in patients with heart failure NYHA III/IV (Prince II Study) [abstract no. 3265]. Circulation 1999 Nov 2; 100 (Suppl.): 619
4. Buckley MM, Sorkin EM. Enoxaparin a review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders. Drugs 1992; 44 (3): 465-97
5. Noble S, Spencer CM. Enoxaparin: a review of its clinical potential in the management of coronary artery disease. Drugs 1998; 56: 259-72
6. Noble S, Peters DH, Goa KL. Enoxaparin: a reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease. Drugs 1995; 49: 388-410
7. Haines ST, Bussey HI. Thrombosis and the pharmacology of antithrombotic agents. Ann Pharmacother 1995; 29 (9): 892-905
8. Xiao Z, Théroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998; 97: 251-6
9. Aventis Pharmaceuticals Products Inc. Lovenox prescribing information. 2000 Collegville, (PA) USA 2000: Aventis Pharmaceuticals Products Inc.
10. Frydman AM, Bara L, Le Roux L, et al. The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol 1988; 28: 609-18
11. Hurst AK, Pickens PA, Chenella FC, et al. Enoxaparin pharmacokinetics in acutely ill hospitalized patients [abstract no. 89]. Pharmacotherapy 2000 Oct; 20 (10): 1244
12. Brophy DF, Wazny LD, Gehr TWB, et al. The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease. Pharmacotherapy 2001 Feb; 21 (2): 169-74
13. Sanderink G J, Guimart C, Jariwala N, et al. Enoxaparin pharmacokinetics and pharmacodynamics in renal impairment [abstract no. 1076-169]. J Am Coll Cardiol 2001 Feb; 37 Suppl. A (2): 229
14. McEvoy GK. AHFS Drug Information. 2001 ed. Bethesda, (MD) American Society of Health-System Pharmacists, 2001